Minrad and Piramal to Merge

Piramal Healthcare Limited will acquire Minrad International for $.12 per share plus the assumption of debt. The total transaction, valued at approximately $40 million, is expected to close in the first quarter of 2009. Piramal, an Indian pharmaceutical giant with a market capitalization north of $45...

NovaDel: Longs May Finally Get a Good Night’s Sleep

The FDA has approved NovaDel’s Zolpimist, an oral spray for the short-term treatment of insomnia. Zolpimist contains zolpidem tartrate, the same active ingredient found in Ambien. Until recently, the U.S. patent for zolpidem was held by the French pharmaceutical giant Sanofi-Aventis. In April 2007, the FDA...

[Incubator Profile] UAMS BioVentures

OneMedPlace would like to welcome UAMS BioVentures as a founding member of our Portfolio Development Group. BioVentures, will discuss its innovative business practices at the upcoming OneMedForum in January. The presentation will include a snap shot of the incubator facility and a brief overview of its top...

[Company Profile] OptiNose

OptiNose’s breath-actuated devices deliver intranasal drugs to targeted regions of the nasal cavity, including the sinuses and the olfactory region, without lung deposition, a major problem for traditional nasal inhalers, nasal sprays or nebulizers. OptiNose technology has significant market potential in...

AngioDynamics’ NanoKnife: “Unique and Remarkable” Absence of Post-Operative Pain

AngioDynamics announced the use of its Irreversible Electroporation (IRE) technology on a lymph node metastasis and the first lung lesion case. The procedures were judged successful from a safety perspective. The hospital will conduct further patient follow-up before determining tumor response. These are the...

CompuMed Secures $4 Million for Strategic Initiatives

CompuMed has secured a $4 million line of credit, allowing the telemedicine company to pursue strategic initiatives even in this challenging financing environment. The funds will provide immediate working capital for growth and potential acquisitions. The new credit facility supersedes a previous agreement...

Citing a Lack of Funds, PLC Systems Defers RenalGuard Trial

It’s been over 18 months since PLC Systems enrolled the first patients in its RenalGuard clinical trial. It now appears the company’s efforts may have been for naught. PLC has deferred the trial pending further funding. RenalGuard received CE Mark approval in late 2007; commercialization efforts in...

Synthes Prevails Against Medtronic

Synthes, a maker of spine and bone implants, has prevailed in a court battle with device-giant Medtronic. Synthes alleged that Medtronic had willfully infringed on patents covering its artificial disc line, ProDisc-L, by launching a competitive line of discs named Maverick. The Memphis, TN-based jury...